Physician profile
Penelope A Jackson
NPI 1548240682
$1,968.88
in general payments reported to CMS, 2019-2025
28 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $390 · 2021: $365 · 2022: $305 · 2023: $221 · 2024: $144 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $561.90 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $272.36 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $184.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $154.01 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $114.86 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $73.60 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $73.52 | 2019-2023 | Pediarix, Bexsero, Menveo |
| Lilly USA, LLC | $53.39 | 2020-2022 | |
| Acella Pharmaceuticals, LLC | $47.93 | 2025 | NP Thyroid 60 |
| Sanofi-Aventis U.S. LLC | $44.28 | 2019-2023 | |
| Pfizer INC. | $41.96 | 2020-2025 | |
| Abbott Laboratories | $35.60 | 2022-2024 | Proclaim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.51 | 2024-2025 | Caplyta |
| Kowa Pharmaceuticals America, INC. | $32.45 | 2021-2023 | Seglentis, Livalo |
| Inspire Medical Systems, INC. | $25.67 | 2025 | Inspire |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $21.89 | 2021 | |
| Halozyme INC | $20.60 | 2023 | |
| Owp Pharmaceuticals, INC. | $19.99 | 2025 | Subvenite |
| Amgen INC. | $17.95 | 2025 | Otezla |
| Sunovion Pharmaceuticals INC. | $17.28 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.05 | 2023 | |
| Tolmar, INC. | $16.23 | 2025 | Jatenzo |
| Exact Sciences Corporation | $16.09 | 2025 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $15.71 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.29 | 2022 | |
| Ibsa Pharma INC. | $14.09 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.14 | 2019 | |
| Currax Pharmaceuticals LLC | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penelope Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.